RMDNEUTRAL

Revenue Growth (YoY)

10.8%

Higher than 67% of Healthcare sector peers

Updated 56h ago

Sector Performance

67th percentile

RMD

10.8%

Sector Median

6.2%

Sector Avg

4.2%

📊

Deep Analysis

Revenue growth year-over-year (YoY) compares a company's current-period sales to the same period one year earlier; a 10.8% increase means RMD generated 10.8% more revenue than it did a year ago.

This rate places RMD above the healthcare sector median of 6.2%, landing it in the 67th percentile among its sector peers. The trend data is not available — the year-over-year change and quarter-over-quarter change are both marked N/A, and only a single historical value of 10.8% is provided. Without a multi-period trend, the metric offers no directional insight into accelerating or decelerating performance. The combination of a moderately above-median level with no trend information creates a neutral risk-opportunity profile, as the current growth is solid but cannot be assessed for momentum. This metric supports the overall NEUTRAL verdict: the growth rate is better than most peers, but the absence of trend data prevents a bullish or bearish tilt.

Frequently Asked Questions

What does the Revenue Growth (YoY) tell investors about RMD?

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.

How is the Revenue Growth (YoY) calculated?

Revenue Growth (YoY) is calculated as: (Revenue_t - Revenue_t-4) / Revenue_t-4.

How does RMD's Revenue Growth (YoY) compare to its sector?

RMD's Revenue Growth (YoY) of 10.8% compares to a Healthcare sector median of 6.2%, placing it in the 67th percentile.

Who are RMD's closest peers by Revenue Growth (YoY)?

The closest Healthcare peers by Revenue Growth (YoY) include: ALGN (6.2%), AMGN (5.8%), CPRX (5.6%), ABT (7.8%), ZBH (9.3%).

The Formula

(Revenue_t - Revenue_t-4) / Revenue_t-4

Why It Matters

Year-over-year revenue acceleration is one of the strongest signals of business momentum. Sustained >15% growth is rare and typically re-rated by the market.